Hologic (HOLX) : Currently there are 12 street experts covering Hologic (HOLX) stock. The most bullish and bearish price target for the stock is $46 and $38 respectively for the short term. The average price target of all the analysts comes to $42.25. The estimated standard deviation from the target is $2.56.
Hologic (HOLX) reported a rise of 49% or 2,870,322 shares in its short interest. The short figure came in at 3.1% of the total floats. The average daily volume of 3,748,641 shares suggests that the days to cover 8,729,223 short positions, as on June 30,2016, will be 2. On June 15,2016, the short interest was 5,858,901 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, Needham downgrades their rating on the shares of Hologic (NASDAQ:HOLX). The current rating of the shares is Hold. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on April 28, 2016.
Hologic (NASDAQ:HOLX): stock turned positive on Thursday. Though the stock opened at $36.06, the bulls momentum made the stock top out at $36.56 level for the day. The stock recorded a low of $36.04 and closed the trading day at $36.53, in the green by 2.04%. The total traded volume for the day was 2,378,818. The stock had closed at $35.8 in the previous days trading.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.